Genotoxicity-Stimulated and CYLD-Driven Malignant Transformation

References

• Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science (80-). 2008;319(5868):1352–1355. doi:10.1126/science.1140735
   PubMed Web of Science ®Google Scholar
• Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461(7267):1071–1078. doi:10.1038/nature08467
   PubMed Web of Science ®Google Scholar
• Lin Y, Bai L, Chen W, Xu S. The NF-κB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin Ther Targets. 2010;14(1):45–55. doi:10.1517/14728220903431069
   PubMed Web of Science ®Google Scholar
• Li H, Marple T, Hasty P. Ku80-deleted cells are defective at base excision repair. Mutat Res Mol Mech Mutagen. 2013;745–746:16–25. doi:10.1016/j.mrfmmm.2013.03.010
   PubMed Web of Science ®Google Scholar
• David SS, O’Shea VL, Kundu S. Base-excision repair of oxidative DNA damage. Nature. 2007;447(7147):941–950. doi:10.1038/nature05978
   PubMed Web of Science ®Google Scholar
• Maynard S, Schurman SH, Harboe C, de Souza-Pinto NC, Bohr VA. Base excision repair of oxidative DNA damage and association with cancer and aging. Carcinogenesis. 2008;30(1):2–10. doi:10.1093/carcin/bgn250
   PubMed Web of Science ®Google Scholar
• Xia W, Ci S, Li M, et al. Two‐way crosstalk between BER and c‐NHEJ repair pathway is mediated by Pol‐β and Ku70. FASEB J. 2019;33(11):11668–11681. doi:10.1096/fj.201900308R
   PubMed Web of Science ®Google Scholar
• Guo Z, Kozlov S, Lavin MF, Person MD, Paull TT. ATM activation by oxidative stress. Science (80-). 2010;330(6003):517–521. doi:10.1126/science.1192912
   PubMed Web of Science ®Google Scholar
• Amrita Sule SE, Golding SF, Farhan JW, et al. ATM phosphorylates PP2A subunit A resulting in nuclear export and spatiotemporal regulation of the DNA damage response. bioRxiv Prepr. 2021. doi:10.1101/2021.08.29.458108
   Google Scholar
• Sun L, Gao J, Huo L, et al. Tumour suppressor CYLD is a negative regulator of the mitotic kinase Aurora-B. J Pathol. 2010;221(4):425–432. doi:10.1002/path.2723
   PubMed Web of Science ®Google Scholar
• Golding SE, Rosenberg E, Valerie N, et al. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol Cancer Ther. 2009;8(10):2894–2902. doi:10.1158/1535-7163.MCT-09-0519
   PubMed Web of Science ®Google Scholar
• Bozulic L, Surucu B, Hynx D, Hemmings BA. PKBα/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol Cell. 2008;30(2):203–213. doi:10.1016/j.molcel.2008.02.024
   PubMed Web of Science ®Google Scholar
• Chowdhury D, Keogh M-C, Ishii H, Peterson CL, Buratowski S, Lieberman J. γ-H2AX dephosphorylation by protein phosphatase 2A facilitates DNA double-strand break repair. Mol Cell. 2005;20(5):801–809. doi:10.1016/j.molcel.2005.10.003
   PubMed Web of Science ®Google Scholar
• Hoeijmakers JHJ. Genome maintenance mechanisms for preventing cancer. Nature. 2001;411(6835):366–374. doi:10.1038/35077232
   PubMed Web of Science ®Google Scholar
• Chou W-C, Wang H-C, Wong F-H, et al. Chk2-dependent phosphorylation of XRCC1 in the DNA damage response promotes base excision repair. EMBO J. 2008;27(23):3140–3150. doi:10.1038/emboj.2008.229
   PubMed Web of Science ®Google Scholar
• Kuhne C. Repair of a minimal DNA double-strand break by NHEJ requires DNA-PKcs and is controlled by the ATM/ATR checkpoint. Nucleic Acids Res. 2003;31(24):7227–7237. doi:10.1093/nar/gkg937
   PubMed Web of Science ®Google Scholar
• Shang Z-F, Huang B, Xu Q-Z, et al. Inactivation of DNA-dependent protein kinase leads to spindle disruption and mitotic catastrophe with attenuated checkpoint protein 2 phosphorylation in response to DNA damage. Cancer Res. 2010;70(9):3657–3666. doi:10.1158/0008-5472.CAN-09-3362
   PubMed Web of Science ®Google Scholar
• Maachani UB, Kramp T, Hanson R, et al. Targeting MPS1 enhances radiosensitization of human glioblastoma by modulating DNA repair proteins. Mol Cancer Res. 2015;13(5):852–862. doi:10.1158/1541-7786.MCR-14-0462-T
   PubMed Web of Science ®Google Scholar
• Wei J-H, Chou Y-F, Ou Y-H, et al. TTK/hMps1 participates in the regulation of DNA damage checkpoint response by phosphorylating CHK2 on threonine 68. J Biol Chem. 2005;280(9):7748–7757. doi:10.1074/jbc.M410152200
   PubMed Web of Science ®Google Scholar
• Yeh C-W, Yu Z-C, Chen P-H, Cheng Y-C, Shieh S-Y. Phosphorylation at threonine 288 by cell cycle Checkpoint Kinase 2 (CHK2) controls human monopolar Spindle 1 (Mps1) kinetochore localization. J Biol Chem. 2014;289(22):15319–15327. doi:10.1074/jbc.M114.552273
   PubMed Web of Science ®Google Scholar
• Yu Z-C, Huang Y-F, Shieh S-Y. Requirement for human Mps1/TTK in oxidative DNA damage repair and cell survival through MDM2 phosphorylation. Nucleic Acids Res. 2016;44(3):1133–1150. doi:10.1093/nar/gkv1173
   PubMed Web of Science ®Google Scholar
• Shang Z, Yu L, Lin Y-F, Matsunaga S, Shen C-Y, Chen BPC. DNA-PKcs activates the Chk2–Brca1 pathway during mitosis to ensure chromosomal stability. Oncogenesis. 2014;3(2):e85–e85. doi:10.1038/oncsis.2013.49
   PubMed Web of Science ®Google Scholar
• Nihira K, Taira N, Miki Y, Yoshida K. TTK/Mps1 controls nuclear targeting of c-Abl by 14-3-3-coupled phosphorylation in response to oxidative stress. Oncogene. 2008;27(58):7285–7295. doi:10.1038/onc.2008.334
   PubMed Web of Science ®Google Scholar
• Dai Z, Pendergast AM. Abi-2, a novel SH3-containing protein interacts with the c-Abl tyrosine kinase and modulates c-Abl transforming activity. Genes Dev. 1995;9(21):2569–2582. doi:10.1101/gad.9.21.2569
   PubMed Web of Science ®Google Scholar
• Wang JYJ. The capable ABL: what is its biological function? Mol Cell Biol. 2014;34(7):1188–1197. doi:10.1128/MCB.01454-13
   PubMed Web of Science ®Google Scholar
• Raina D, Ahmad R, Kumar S, et al. MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage. EMBO J. 2006;25(16):3774–3783. doi:10.1038/sj.emboj.7601263
   PubMed Web of Science ®Google Scholar
• Raina D, Ahmad R, Chen D, Kumar S, Kharbanda S, Kufe DW. Muc1 oncoprotein suppresses activation of the ARF-MDM2-p53 pathway. Cancer Biol Ther. 2008;7(12):1959–1967. doi:10.4161/cbt.7.12.6956
   PubMed Web of Science ®Google Scholar
• Kawai H, Nie L, Yuan Z-M. Inactivation of NF-κB-dependent cell survival, a novel mechanism for the proapoptotic function of c-Abl. Mol Cell Biol. 2002;22(17):6079–6088. doi:10.1128/MCB.22.17.6079-6088.2002
   PubMed Web of Science ®Google Scholar
• Shafman T, Khanna KK, Kedar P, et al. Interaction between ATM protein and c-Abl in response to DNA damage. Nature. 1997;387(6632):520–523. doi:10.1038/387520a0
   PubMed Web of Science ®Google Scholar
• Shaul Y, Ben-Yehoyada M. Role of c-Abl in the DNA damage stress response. Cell Res. 2005;15(1):33–35. doi:10.1038/sj.cr.7290261
   PubMed Web of Science ®Google Scholar
• Kharbanda S, Pandey P, Jin S, et al. Functional interaction between DNA-PK and c-Abl in response to DNA damage. Nature. 1997;386(6626):732–735. doi:10.1038/386732a0
   PubMed Web of Science ®Google Scholar
• Aoyama K, Yamaguchi N, Yuki R, et al. c-Abl induces stabilization of histone deacetylase 1 (HDAC1) in a kinase activity-dependent manner. Cell Biol Int. 2015;39(4):446–456. doi:10.1002/cbin.10413
   PubMed Web of Science ®Google Scholar
• Liberatore RA, Goff SP, Nunes I. NF-κB activity is constitutively elevated in c-Abl null fibroblasts. Proc Natl Acad Sci. 2009;106(42):17823–17828. doi:10.1073/pnas.0905935106
   PubMed Web of Science ®Google Scholar
• Sun Y, Jiang X, Xu Y, et al. Histone H3 methylation links DNA damage detection to activation of the tumour suppressor Tip60. Nat Cell Biol. 2009;11(11):1376–1382. doi:10.1038/ncb1982
   PubMed Web of Science ®Google Scholar
• Blackford AN, Jackson SP. ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response. Mol Cell. 2017;66(6):801–817. doi:10.1016/j.molcel.2017.05.015
   PubMed Web of Science ®Google Scholar
• Jiang Z, Kamath R, Jin S, Balasubramani M, Pandita TK, Rajasekaran B. Tip60-mediated acetylation activates transcription independent apoptotic activity of Abl. Mol Cancer. 2011;10(1):88. doi:10.1186/1476-4598-10-88
   PubMed Web of Science ®Google Scholar
• Wang W, Li M, Ponnusamy S, et al. ABL1-dependent OTULIN phosphorylation promotes genotoxic Wnt/β-catenin activation to enhance drug resistance in breast cancers. Nat Commun. 2020;11(1):3965. doi:10.1038/s41467-020-17770-9
   PubMed Web of Science ®Google Scholar
• Keusekotten K, Elliott PR, Glockner L, et al. OTULIN antagonizes LUBAC signaling by specifically hydrolyzing Met1-linked polyubiquitin. Cell. 2013;153(6):1312–1326. doi:10.1016/j.cell.2013.05.014
   PubMed Web of Science ®Google Scholar
• Elliott PR, Nielsen SV, Marco-Casanova P, et al. Molecular basis and regulation of OTULIN-LUBAC interaction. Mol Cell. 2014;54(3):335–348. doi:10.1016/j.molcel.2014.03.018
   PubMed Web of Science ®Google Scholar
• Takiuchi T, Nakagawa T, Tamiya H, et al. Suppression of LUBAC-mediated linear ubiquitination by a specific interaction between LUBAC and the deubiquitinases CYLD and OTULIN. Genes Cells. 2014;19(3):254–272. doi:10.1111/gtc.12128
   PubMed Web of Science ®Google Scholar
• Tao P, Wang S, Ozen S, et al. Deubiquitination of proteasome subunits by OTULIN regulates type I IFN production. Sci Adv. 2021;7:47. doi:10.1126/sciadv.abi6794
   Web of Science ®Google Scholar
• Di Costanzo A, Del Gaudio N, Conte L, Altucci L. The ubiquitin proteasome system in hematological malignancies: new insight into its functional role and therapeutic options. Cancers. 2020;12(7):1898. doi:10.3390/cancers12071898
   PubMed Web of Science ®Google Scholar
• Elliott PR, Leske D, Hrdinka M, et al. SPATA2 Links CYLD to LUBAC, activates CYLD, and controls LUBAC signaling. Mol Cell. 2016;63(6):990–1005. doi:10.1016/j.molcel.2016.08.001
   PubMed Web of Science ®Google Scholar
• Douglas T, Saleh M. Post-translational modification of OTULIN regulates ubiquitin dynamics and cell death. Cell Rep. 2019;29(11):3652–3663.e5. doi:10.1016/j.celrep.2019.11.014
   PubMed Web of Science ®Google Scholar
• Elliott PR, Leske D, Wagstaff J, et al. Regulation of CYLD activity and specificity by phosphorylation and ubiquitin-binding CAP-Gly domains. Cell Rep. 2021;37(1):109777. doi:10.1016/j.celrep.2021.109777
   PubMed Web of Science ®Google Scholar
• Hrdinka M, Gyrd-Hansen M. The Met1-linked ubiquitin machinery: emerging themes of (De)regulation. Mol Cell. 2017;68(2):265–280. doi:10.1016/j.molcel.2017.09.001
   PubMed Web of Science ®Google Scholar
• Bignell GR, Warren W, Seal S, et al. Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet. 2000;25(2):160–165. doi:10.1038/76006
   PubMed Web of Science ®Google Scholar
• Gao J, Huo L, Sun X, et al. The tumor suppressor CYLD regulates microtubule dynamics and plays a role in cell migration. J Biol Chem. 2008;283(14):8802–8809. doi:10.1074/jbc.M708470200
   PubMed Web of Science ®Google Scholar
• Saito K, Kigawa T, Koshiba S, et al. The CAP-Gly domain of CYLD associates with the proline-rich sequence in NEMO/IKKγ. Structure. 2004;12(9):1719–1728. doi:10.1016/j.str.2004.07.012
   PubMed Web of Science ®Google Scholar
• Uematsu A, Kido K, Takahashi H, et al. The E3 ubiquitin ligase MIB2 enhances inflammation by degrading the deubiquitinating enzyme CYLD. J Biol Chem. 2019;294(38):14135–14148. doi:10.1074/jbc.RA119.010119
   PubMed Web of Science ®Google Scholar
• Reiley W, Zhang M, Wu X, Granger E, Sun S-C. Regulation of the deubiquitinating enzyme CYLD by IκB kinase gamma-dependent phosphorylation. Mol Cell Biol. 2005;25(10):3886–3895. doi:10.1128/MCB.25.10.3886-3895.2005
   PubMed Web of Science ®Google Scholar
• Hutti JE, Shen RR, Abbott DW, et al. Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKɛ promotes cell transformation. Mol Cell. 2009;34(4):461–472. doi:10.1016/j.molcel.2009.04.031
   PubMed Web of Science ®Google Scholar
• Heger K, Wickliffe KE, Ndoja A, et al. OTULIN limits cell death and inflammation by deubiquitinating LUBAC. Nature. 2018;559(7712):120–124. doi:10.1038/s41586-018-0256-2
   PubMed Web of Science ®Google Scholar
• Weinelt N, van Wijk SJL. Ubiquitin-dependent and -independent functions of OTULIN in cell fate control and beyond. Cell Death Differ. 2021;28(2):493–504. doi:10.1038/s41418-020-00675-x
   PubMed Web of Science ®Google Scholar
• Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science (80-). 2002;296(5573):1634–1635. doi:10.1126/science.1071924
   PubMed Web of Science ®Google Scholar
• Westbrook AM, Wei B, Hacke K, Xia M, Braun J, Schiestl RH. The role of tumour necrosis factor- and tumour necrosis factor receptor signalling in inflammation-associated systemic genotoxicity. Mutagenesis. 2012;27(1):77–86. doi:10.1093/mutage/ger063
   PubMed Web of Science ®Google Scholar
• Ozsoy HZ, Sivasubramanian N, Wieder ED, Pedersen S, Mann DL. Oxidative stress promotes ligand-independent and enhanced ligand-dependent tumor necrosis factor receptor signaling. J Biol Chem. 2008;283(34):23419–23428. doi:10.1074/jbc.M802967200
   PubMed Web of Science ®Google Scholar
• Fernández-Majada V, Welz P-S, Ermolaeva MA, et al. The tumour suppressor CYLD regulates the p53 DNA damage response. Nat Commun. 2016;7(1):12508. doi:10.1038/ncomms12508
   PubMed Web of Science ®Google Scholar
• McCool KW, Miyamoto S. DNA damage-dependent NF-κB activation: NEMO turns nuclear signaling inside out. Immunol Rev. 2012;246(1):311–326. doi:10.1111/j.1600-065X.2012.01101.x
   PubMed Web of Science ®Google Scholar
• Hur GM, Lewis J, Yang Q, et al. The death domain kinase RIP has an essential role in DNA damage-induced NF-κB activation. Genes Dev. 2003;17(7):873–882. doi:10.1101/gad.1062403
   PubMed Web of Science ®Google Scholar
• Biton S, Ashkenazi A. NEMO and RIP1 control cell fate in response to extensive DNA damage via TNF-α feedforward signaling. Cell. 2011;145(1):92–103. doi:10.1016/j.cell.2011.02.023
   PubMed Web of Science ®Google Scholar
• Blackwell K, Zhang L, Thomas GS, Sun S, Nakano H, Habelhah H. TRAF2 phosphorylation modulates tumor necrosis factor alpha-induced gene expression and cell resistance to apoptosis. Mol Cell Biol. 2009;29(2):303–314. doi:10.1128/MCB.00699-08
   PubMed Web of Science ®Google Scholar
• Park E-S, Choi S, Shin B, et al. Tumor necrosis factor (TNF) receptor-associated factor (TRAF)-interacting protein (TRIP) negatively regulates the TRAF2 ubiquitin-dependent pathway by suppressing the TRAF2-Sphingosine 1-Phosphate (S1P) interaction. J Biol Chem. 2015;290(15):9660–9673. doi:10.1074/jbc.M114.609685
   PubMed Web of Science ®Google Scholar
• Alvarez SE, Harikumar KB, Hait NC, et al. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature. 2010;465(7301):1084–1088. doi:10.1038/nature09128
   PubMed Web of Science ®Google Scholar
• Shi C-S, Kehrl JH. Activation of stress-activated protein Kinase/c-Jun N-terminal kinase, but not NF-κB, by the Tumor Necrosis Factor (TNF) receptor 1 through a TNF receptor-associated factor 2- and germinal center kinase related-dependent pathway. J Biol Chem. 1997;272(51):32102–32107. doi:10.1074/jbc.272.51.32102
   PubMed Web of Science ®Google Scholar
• Tournier C, Dong C, Turner TK, Jones SN, Flavell RA, Davis RJ. MKK7 is an essential component of the JNK signal transduction pathway activated by proinflammatory cytokines. Genes Dev. 2001;15(11):1419–1426. doi:10.1101/gad.888501
   PubMed Web of Science ®Google Scholar
• Ventura -J-J, Kennedy NJ, Lamb JA, Flavell RA, Davis RJ. c-Jun NH 2 -terminal kinase is essential for the regulation of AP-1 by tumor necrosis factor. Mol Cell Biol. 2003;23(8):2871–2882. doi:10.1128/MCB.23.8.2871-2882.2003
   PubMed Web of Science ®Google Scholar
• Pomerantz JL. NF-kappa B activation by a signaling complex containing TRAF2, TANK and TBK1, a novel IKK-related kinase. EMBO J. 1999;18(23):6694–6704. doi:10.1093/emboj/18.23.6694
   PubMed Web of Science ®Google Scholar
• Vince JE, Pantaki D, Feltham R, et al. TRAF2 must bind to cellular inhibitors of apoptosis for tumor necrosis factor (TNF) to efficiently activate NF-κB and to prevent TNF-induced apoptosis. J Biol Chem. 2009;284(51):35906–35915. doi:10.1074/jbc.M109.072256
   PubMed Web of Science ®Google Scholar
• Zhou AY, Shen RR, Kim E, et al. IKKε-mediated tumorigenesis requires K63-linked polyubiquitination by a cIAP1/cIAP2/TRAF2 E3 ubiquitin ligase complex. Cell Rep. 2013;3(3):724–733. doi:10.1016/j.celrep.2013.01.031
   PubMed Web of Science ®Google Scholar
• Shen RR, Zhou AY, Kim E, Lim E, Habelhah H, Hahn WC. IκB kinase ε phosphorylates TRAF2 to promote mammary epithelial cell transformation. Mol Cell Biol. 2012;32(23):4756–4768. doi:10.1128/MCB.00468-12
   PubMed Web of Science ®Google Scholar
• Annibaldi A, Wicky John S, Vanden Berghe T, et al. Ubiquitin-mediated regulation of RIPK1 kinase activity independent of IKK and MK2. Mol Cell. 2018;69(4):566–580.e5. doi:10.1016/j.molcel.2018.01.027
   PubMed Web of Science ®Google Scholar
• Haas TL, Emmerich CH, Gerlach B, et al. Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. Mol Cell. 2009;36(5):831–844. doi:10.1016/j.molcel.2009.10.013
   PubMed Web of Science ®Google Scholar
• Nakatsu Y, Matsuoka M, Chang T-H, et al. Functionally distinct effects of the C-Terminal regions of IKKε and TBK1 on Type I IFN production. PLoS One. 2014;9(4):e94999. doi:10.1371/journal.pone.0094999
   PubMed Web of Science ®Google Scholar
• Sun S-C. CYLD: a tumor suppressor deubiquitinase regulating NF-κB activation and diverse biological processes. Cell Death Differ. 2010;17(1):25–34. doi:10.1038/cdd.2009.43
   PubMed Web of Science ®Google Scholar
• Marié I, Smith E, Prakash A, Levy DE. Phosphorylation-induced dimerization of interferon regulatory factor 7 unmasks DNA binding and a bipartite transactivation domain. Mol Cell Biol. 2000;20(23):8803–8814. doi:10.1128/MCB.20.23.8803-8814.2000
   PubMed Web of Science ®Google Scholar
• Feltham R, Jamal K, Tenev T, et al. Mind bomb regulates cell death during TNF signaling by suppressing RIPK1ʹs cytotoxic potential. Cell Rep. 2018;23(2):470–484. doi:10.1016/j.celrep.2018.03.054
   PubMed Web of Science ®Google Scholar
• Nakabayashi O, Takahashi H, Moriwaki K, et al. MIND bomb 2 prevents RIPK1 kinase activity-dependent and -independent apoptosis through ubiquitylation of cFLIPL. Commun Biol. 2021;4(1):80. doi:10.1038/s42003-020-01603-y
   PubMed Web of Science ®Google Scholar
• Rajan N, Elliott RJR, Smith A, et al. The cylindromatosis gene product, CYLD, interacts with MIB2 to regulate Notch signalling. Oncotarget. 2014;5(23):12126–12140. doi:10.18632/oncotarget.2573
   PubMedGoogle Scholar
• Stempin CC, Chi L, Giraldo-Vela JP, High AA, Häcker H, Redecke V. The E3 ubiquitin ligase mind bomb-2 (MIB2) protein controls B-cell CLL/lymphoma 10 (BCL10)-dependent NF-κB activation. J Biol Chem. 2011;286(43):37147–37157. doi:10.1074/jbc.M111.263384
   PubMed Web of Science ®Google Scholar
• Chen I-T, Hsu P-H, Hsu W-C, Chen N-J, Tseng P-H. Polyubiquitination of transforming growth factor β-activated Kinase 1 (TAK1) at Lysine 562 residue regulates TLR4-mediated JNK and p38 MAPK Activation. Sci Rep. 2015;5(1):12300. doi:10.1038/srep12300
   PubMed Web of Science ®Google Scholar
• Zhao Y, Ma CA, Wu L, et al. CYLD and the NEMO zinc finger regulate tumor necrosis factor signaling and early embryogenesis. J Biol Chem. 2015;290(36):22076–22084. doi:10.1074/jbc.M115.658096
   PubMed Web of Science ®Google Scholar
• Ahmed N, Zeng M, Sinha I, et al. The E3 ligase Itch and deubiquitinase Cyld act together to regulate Tak1 and inflammation. Nat Immunol. 2011;12(12):1176–1183. doi:10.1038/ni.2157
   PubMed Web of Science ®Google Scholar
• Moreno-García ME, Sommer K, Rincon-Arano H, et al. Kinase-Independent Feedback of the TAK1/TAB1 Complex on BCL10 Turnover and NF-κB Activation. Mol Cell Biol. 2013;33(6):1149–1163. doi:10.1128/MCB.06407-11
   PubMed Web of Science ®Google Scholar
• Le Clorennec C, Lazrek Y, Dubreuil O, et al. ITCH-dependent proteasomal degradation of c-FLIP induced by the anti-HER3 antibody 9F7-F11 promotes DR5/caspase 8-mediated apoptosis of tumor cells. Cell Commun Signal. 2019;17(1):106. doi:10.1186/s12964-019-0413-8
   PubMed Web of Science ®Google Scholar
• Wei R, Xu LW, Liu J, et al. SPATA2 regulates the activation of RIPK1 by modulating linear ubiquitination. Genes Dev. 2017;31(11):1162–1176. doi:10.1101/gad.299776.117
   PubMed Web of Science ®Google Scholar
• Tang Y, Joo D, Liu G, et al. Linear ubiquitination of cFLIP induced by LUBAC contributes to TNFα-induced apoptosis. J Biol Chem. 2018;293(52):20062–20072. doi:10.1074/jbc.RA118.005449
   PubMed Web of Science ®Google Scholar
• Peltzer N, Darding M, Montinaro A, et al. LUBAC is essential for embryogenesis by preventing cell death and enabling haematopoiesis. Nature. 2018;557(7703):112–117. doi:10.1038/s41586-018-0064-8
   PubMed Web of Science ®Google Scholar
• Lafont E, Kantari‐Mimoun C, Draber P, et al. The linear ubiquitin chain assembly complex regulates TRAIL ‐induced gene activation and cell death. EMBO J. 2017;36(9):1147–1166. doi:10.15252/embj.201695699
   PubMed Web of Science ®Google Scholar
• Tu H, Tang Y, Zhang J, et al. Linear ubiquitination of RIPK1 on Lys612 regulates systemic inflammation via preventing cell death. J Immunol. 2021;207(2):602–612. doi:10.4049/jimmunol.2100299
   PubMed Web of Science ®Google Scholar
• Kanayama A, Seth RB, Sun L, et al. TAB2 and TAB3 activate the NF-κB pathway through binding to polyubiquitin chains. Mol Cell. 2004;15(4):535–548. doi:10.1016/j.molcel.2004.08.008
   PubMed Web of Science ®Google Scholar
• Jaco I, Annibaldi A, Lalaoui N, et al. MK2 phosphorylates RIPK1 to prevent TNF-induced cell death. Mol Cell. 2017;66(5):698–710.e5. doi:10.1016/j.molcel.2017.05.003
   PubMed Web of Science ®Google Scholar
• Emmerich CH, Ordureau A, Strickson S, et al. Activation of the canonical IKK complex by K63/M1-linked hybrid ubiquitin chains. Proc Natl Acad Sci. 2013;110(38):15247–15252. doi:10.1073/pnas.1314715110
   PubMed Web of Science ®Google Scholar
• Zhang J, Clark K, Lawrence T, Peggie MW, Cohen P. An unexpected twist to the activation of IKKβ: TAK1 primes IKKβ for activation by autophosphorylation. Biochem J. 2014;461(3):531–537. doi:10.1042/BJ20140444
   PubMed Web of Science ®Google Scholar
• Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, Mosialos G. CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members. Nature. 2003;424(6950):793–796. doi:10.1038/nature01803
   PubMed Web of Science ®Google Scholar
• Lim JW, Kim H, Kim KH. Expression of Ku70 and Ku80 mediated by NF-κB and Cyclooxygenase-2 is related to proliferation of human gastric cancer cells. J Biol Chem. 2002;277(48):46093–46100. doi:10.1074/jbc.M206603200
   PubMed Web of Science ®Google Scholar
• Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J. NF-κB signals induce the expression of c-FLIP. Mol Cell Biol. 2001;21(16):5299–5305. doi:10.1128/MCB.21.16.5299-5305.2001
   PubMed Web of Science ®Google Scholar
• Sakamoto K, Hikiba Y, Nakagawa H, et al. Promotion of DNA repair by nuclear IKKβ phosphorylation of ATM in response to genotoxic stimuli. Oncogene. 2013;32(14):1854–1862. doi:10.1038/onc.2012.192
   PubMed Web of Science ®Google Scholar
• Boehm JS, Zhao JJ, Yao J, et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell. 2007;129(6):1065–1079. doi:10.1016/j.cell.2007.03.052
   PubMed Web of Science ®Google Scholar
• Creixell P, Schoof EM, Tan CSH, Linding R. Mutational properties of amino acid residues: implications for evolvability of phosphorylatable residues. Philos Trans R Soc B Biol Sci. 2012;367(1602):2584–2593. doi:10.1098/rstb.2012.0076
   PubMed Web of Science ®Google Scholar
• Mészáros B, Hajdu-Soltész B, Zeke A, Dosztányi Z. Mutations of intrinsically disordered protein regions can drive cancer but lack therapeutic strategies. Biomolecules. 2021;11(3):381. doi:10.3390/biom11030381
   PubMed Web of Science ®Google Scholar
• Pajkos M, Zeke A, Dosztányi Z. Ancient evolutionary origin of intrinsically disordered cancer risk regions. Biomolecules. 2020;10(8):1115. doi:10.3390/biom10081115
   PubMed Web of Science ®Google Scholar
• Asselman J, De Coninck DI, Beert E, et al. Bisulfite sequencing with daphnia highlights a role for epigenetics in regulating stress response to microcystis through preferential differential methylation of serine and threonine amino acids. Environ Sci Technol. 2017;51(2):924–931. doi:10.1021/acs.est.6b03870
   PubMed Web of Science ®Google Scholar
• Greuber EK, Smith-Pearson P, Wang J, Pendergast AM. Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat Rev Cancer. 2013;13(8):559–571. doi:10.1038/nrc3563
   PubMed Web of Science ®Google Scholar
• Bieging KT, Mello SS, Attardi LD. Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer. 2014;14(5):359–370. doi:10.1038/nrc3711
   PubMed Web of Science ®Google Scholar
• Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell. 2012;21(3):297–308. doi:10.1016/j.ccr.2012.02.014
   PubMed Web of Science ®Google Scholar
• Liu Y, Gu W. The complexity of p53-mediated metabolic regulation in tumor suppression. Semin Cancer Biol. 2021. doi:10.1016/j.semcancer.2021.03.010
   Web of Science ®Google Scholar
• Bensaad K, Tsuruta A, Selak MA, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell. 2006;126(1):107–120. doi:10.1016/j.cell.2006.05.036
   PubMed Web of Science ®Google Scholar
• Franklin DA, He Y, Leslie PL, et al. p53 coordinates DNA repair with nucleotide synthesis by suppressing PFKFB3 expression and promoting the pentose phosphate pathway. Sci Rep. 2016;6(1):38067. doi:10.1038/srep38067
   PubMed Web of Science ®Google Scholar
• Wang L, Lin Y, Zhou X, et al. CYLD deficiency enhances metabolic reprogramming and tumor progression in nasopharyngeal carcinoma via PFKFB3. Cancer Lett. 2022;532:215586. doi:10.1016/j.canlet.2022.215586
   PubMed Web of Science ®Google Scholar
• Massoumi R, Chmielarska K, Hennecke K, Pfeifer A, Fässler R. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-κB signaling. Cell. 2006;125(4):665–677. doi:10.1016/j.cell.2006.03.041
   PubMed Web of Science ®Google Scholar
• Chang T-P, Vancurova I. Bcl3 regulates pro-survival and pro-inflammatory gene expression in cutaneous T-cell lymphoma. Biochim Biophys Acta - Mol Cell Res. 2014;1843(11):2620–2630. doi:10.1016/j.bbamcr.2014.07.012
   Web of Science ®Google Scholar
• Erol A. IKK-mediated CYLD phosphorylation and cellular redox activity. Mol Med. 2022;28(1):14. doi:10.1186/s10020-022-00439-y
   PubMed Web of Science ®Google Scholar
• Rojo de la Vega M, Chapman E, Zhang DD. NRF2 and the hallmarks of cancer. Cancer Cell. 2018;34(1):21–43. doi:10.1016/j.ccell.2018.03.022
   PubMed Web of Science ®Google Scholar
• Manea A, Tanase LI, Raicu M, Simionescu M. Transcriptional regulation of NADPH oxidase isoforms, Nox1 and Nox4, by nuclear factor-κB in human aortic smooth muscle cells. Biochem Biophys Res Commun. 2010;396(4):901–907. doi:10.1016/j.bbrc.2010.05.019
   PubMed Web of Science ®Google Scholar
• Haq S, Sarodaya N, Karapurkar JK, et al. CYLD destabilizes NoxO1 protein by promoting ubiquitination and regulates prostate cancer progression. Cancer Lett. 2022;525:146–157. doi:10.1016/j.canlet.2021.10.032
   PubMed Web of Science ®Google Scholar
• Skonieczna M, Hejmo T, Poterala-Hejmo A, Cieslar-Pobuda A, Buldak RJ. NADPH oxidases: insights into selected functions and mechanisms of action in cancer and stem cells. Oxid Med Cell Longev. 2017;2017:1–15. doi:10.1155/2017/9420539
   Web of Science ®Google Scholar
• Stegmeier F, Sowa ME, Nalepa G, Gygi SP, Harper JW, Elledge SJ. The tumor suppressor CYLD regulates entry into mitosis. Proc Natl Acad Sci. 2007;104(21):8869–8874. doi:10.1073/pnas.0703268104
   PubMed Web of Science ®Google Scholar
• Liccardi G, Ramos Garcia L, Tenev T, et al. RIPK1 and Caspase-8 ensure chromosome stability independently of their role in cell death and inflammation. Mol Cell. 2019;73(3):413–428.e7. doi:10.1016/j.molcel.2018.11.010
   PubMed Web of Science ®Google Scholar
• li D, Gao J, Yang Y, et al. CYLD coordinates with EB1 to regulate microtubule dynamics and cell migration. Cell Cycle. 2014;13(6):974–983. doi:10.4161/cc.27838
   PubMed Web of Science ®Google Scholar
• Wu J, Huang Y-F, Zhou X-K, et al. Skp2 is required for Aurora B activation in cell mitosis and spindle checkpoint. Cell Cycle. 2015;14(24):3877–3884. doi:10.1080/15384101.2015.1120916
   PubMed Web of Science ®Google Scholar
• Sun L, Gao J, Dong X, et al. EB1 promotes Aurora-B kinase activity through blocking its inactivation by protein phosphatase 2A. Proc Natl Acad Sci. 2008;105(20):7153–7158. doi:10.1073/pnas.0710018105
   PubMed Web of Science ®Google Scholar
• Tauriello DVF, Haegebarth A, Kuper I, et al. Loss of the tumor suppressor CYLD enhances Wnt/β-Catenin signaling through K63-linked ubiquitination of Dvl. Mol Cell. 2010;37(5):607–619. doi:10.1016/j.molcel.2010.01.035
   PubMed Web of Science ®Google Scholar
• van Andel H, Kocemba KA, de Haan-Kramer A, et al. Loss of CYLD expression unleashes Wnt signaling in multiple myeloma and is associated with aggressive disease. Oncogene. 2017;36(15):2105–2115. doi:10.1038/onc.2016.368
   PubMed Web of Science ®Google Scholar
• Yang Y, Liu M, Li D, et al. CYLD regulates spindle orientation by stabilizing astral microtubules and promoting dishevelled-NuMA-dynein/dynactin complex formation. Proc Natl Acad Sci. 2014;111(6):2158–2163. doi:10.1073/pnas.1319341111
   PubMed Web of Science ®Google Scholar
• Wickström SA, Masoumi KC, Khochbin S, Fässler R, Massoumi R. CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin. EMBO J. 2010;29(1):131–144. doi:10.1038/emboj.2009.317
   PubMed Web of Science ®Google Scholar
• Hubbert C, Guardiola A, Shao R, et al. HDAC6 is a microtubule-associated deacetylase. Nature. 2002;417(6887):455–458. doi:10.1038/417455a
   PubMed Web of Science ®Google Scholar
• Lee Y-S, Lim K-H, Guo X, et al. The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. Cancer Res. 2008;68(18):7561–7569. doi:10.1158/0008-5472.CAN-08-0188
   PubMed Web of Science ®Google Scholar
• Rodgers MA, Bowman JW, Fujita H, et al. The linear ubiquitin assembly complex (LUBAC) is essential for NLRP3 inflammasome activation. J Exp Med. 2014;211(7):1333–1347. doi:10.1084/jem.20132486
   PubMed Web of Science ®Google Scholar
• Rébé C, Ghiringhelli F. Interleukin-1β and Cancer. Cancers. 2020;12(7):1791. doi:10.3390/cancers12071791
   PubMed Web of Science ®Google Scholar
• Chariot A, Leonardi A, Müller J, Bonif M, Brown K, Siebenlist U. Association of the adaptor TANK with the IκB Kinase (IKK) regulator NEMO connects IKK complexes with IKKε and TBK1 kinases. J Biol Chem. 2002;277(40):37029–37036. doi:10.1074/jbc.M205069200
   PubMed Web of Science ®Google Scholar
• Tu D, Zhu Z, Zhou AY, et al. Structure and ubiquitination-dependent activation of TANK-binding Kinase 1. Cell Rep. 2013;3(3):747–758. doi:10.1016/j.celrep.2013.01.033
   PubMed Web of Science ®Google Scholar
• Durand J, Zhang Q, Baldwin A. Roles for the IKK-related kinases TBK1 and IKKε in cancer. Cells. 2018;7(9):139. doi:10.3390/cells7090139
   PubMed Web of Science ®Google Scholar
• Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007;129(7):1261–1274. doi:10.1016/j.cell.2007.06.009
   PubMed Web of Science ®Google Scholar
• Xie X, Zhang D, Zhao B, et al. IκB kinase ε and TANK-binding kinase 1 activate AKT by direct phosphorylation. Proc Natl Acad Sci. 2011;108(16):6474–6479. doi:10.1073/pnas.1016132108
   PubMed Web of Science ®Google Scholar
• Goktuna Sİ. IKBKE inhibits TSC1 to activate the mTOR/S6K pathway for oncogenic transformation. TURKISH J Biol. 2018;42(4):268–278. doi:10.3906/biy-1801-57
   PubMed Web of Science ®Google Scholar
• Bodur C, Kazyken D, Huang K, et al. The IKK‐related kinase TBK1 activates mTORC1 directly in response to growth factors and innate immune agonists. EMBO J. 2018;37(1):19–38. doi:10.15252/embj.201696164
   PubMed Web of Science ®Google Scholar
• Tooley AS, Kazyken D, Bodur C, Gonzalez IE, Fingar DC. The innate immune kinase TBK1 directly increases mTORC2 activity and downstream signaling to Akt. J Biol Chem. 2021;297(2):100942. doi:10.1016/j.jbc.2021.100942
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Answering the ultimate question “What is the Proximal Cause of Aging?”. Aging. 2012;4(12):861–877. doi:10.18632/aging.100525
   PubMedGoogle Scholar
• Blagosklonny MV. The hyperfunction theory of aging: three common misconceptions. Oncoscience. 2021;8:103–107. doi:10.18632/oncoscience.545
   PubMedGoogle Scholar
• Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12(1):21–35. doi:10.1038/nrm3025
   PubMed Web of Science ®Google Scholar
• Page A, Navarro M, Suárez-Cabrera C, Bravo A, Ramirez A. Context-dependent role of IKKβ in cancer. Genes. 2017;8(12):376. doi:10.3390/genes8120376
   PubMed Web of Science ®Google Scholar
• Wei Y, Zhao Q, Gao Z, et al. The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy. J Clin Invest. 2019;129(8):3347–3360. doi:10.1172/JCI127726
   PubMed Web of Science ®Google Scholar
• Antonangeli F, Natalini A, Garassino MC, Sica A, Santoni A, Di Rosa F. Regulation of PD-L1 Expression by NF-κB in Cancer. Front Immunol. 2020;11. doi:10.3389/fimmu.2020.584626
   PubMed Web of Science ®Google Scholar
• Belgnaoui SM, Paz S, Samuel S, et al. Linear ubiquitination of NEMO negatively regulates the interferon antiviral response through disruption of the MAVS-TRAF3 complex. Cell Host Microbe. 2012;12(2):211–222. doi:10.1016/j.chom.2012.06.009
   PubMed Web of Science ®Google Scholar
• Musella M, Galassi C, Manduca N, Sistigu A. The Yin and Yang of Type I IFNs in cancer promotion and immune activation. Biology. 2021;10(9):856. doi:10.3390/biology10090856
   PubMed Web of Science ®Google Scholar
• Baydoun HH, Bai XT, Shelton S, Nicot C. HTLV-I tax increases genetic instability by inducing DNA double strand breaks during DNA replication and switching repair to NHEJ. PLoS One. 2012;7(8):e42226. doi:10.1371/journal.pone.0042226
   PubMed Web of Science ®Google Scholar
• Bunting SF, Nussenzweig A. End-joining, translocations and cancer. Nat Rev Cancer. 2013;13(7):443–454. doi:10.1038/nrc3537
   PubMed Web of Science ®Google Scholar
• Pannem RR, Dorn C, Ahlqvist K, Bosserhoff AK, Hellerbrand C, Massoumi R. CYLD controls c-MYC expression through the JNK-dependent signaling pathway in hepatocellular carcinoma. Carcinogenesis. 2014;35(2):461–468. doi:10.1093/carcin/bgt335
   PubMed Web of Science ®Google Scholar
• Poli V, Fagnocchi L, Fasciani A, et al. MYC-driven epigenetic reprogramming favors the onset of tumorigenesis by inducing a stem cell-like state. Nat Commun. 2018;9(1):1024. doi:10.1038/s41467-018-03264-2
   PubMed Web of Science ®Google Scholar
• Alameda JP, Ramírez Á, García-Fernández RA, et al. Premature aging and cancer development in transgenic mice lacking functional CYLD. Aging. 2019;11(1):127–159. doi:10.18632/aging.101732
   PubMedGoogle Scholar
• Khatri A, Wang J, Pendergast AM. Multifunctional Abl kinases in health and disease. J Cell Sci. 2016;129(1):9–16. doi:10.1242/jcs.175521
   PubMed Web of Science ®Google Scholar
• Strobelt R, Adler J, Paran N, et al. Imatinib inhibits SARS-CoV-2 infection by an off-target-mechanism. Sci Rep. 2022;12(1):5758. doi:10.1038/s41598-022-09664-1
   PubMed Web of Science ®Google Scholar
• Hantschel O, Wiesner S, Güttler T, et al. Structural basis for the cytoskeletal association of Bcr-Abl/c-Abl. Mol Cell. 2005;19(4):461–473. doi:10.1016/j.molcel.2005.06.030
   PubMed Web of Science ®Google Scholar
• Yuan Z-M, Shioya H, Ishiko T, et al. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature. 1999;399(6738):814–817. doi:10.1038/21704
   PubMed Web of Science ®Google Scholar